ClinicalTrials.gg

Program

pemvidutide

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Alcoholism, led by Altimmune.

Furthest: phase 3, since Aug 14, 20265 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Altimmune52 open or runningphase 3since Aug 14, 2026Jul 14, 2021Sep 30, 2027phase 2 · NCT07009860

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2021First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT04972396 · 40 enrolled · Australia
  2. Jul 24, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05989711 · 212 enrolled · United States, Australia, Puerto Rico
  3. May 16, 2025Phase 2 study in AlcoholismNCT06987513 · 100 enrolled · United States
  4. Jun 5, 2025Phase 2 study in Alcohol-associated Liver DiseaseNCT07009860 · 121 enrolled · United States, Puerto Rico
  5. Aug 14, 2026Phase 3 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 3 reachedNCT07795164 · 1,800 planned · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 2 study in Alcohol-associated Liver DiseaseNCT07009860
  2. Dec 2028Primary completion: phase 3 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07795164

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07795164Metabolic Dysfunction-Associated Steatohepatitis (MASH) · United States3RecruitingDec 20281,800
NCT07009860Alcohol-associated Liver Disease · United States, Puerto Rico2Active, not recruitingSep 30, 2027121
NCT06987513Alcoholism · United States2CompletedJul 30, 2026100
NCT05989711Non-alcoholic Fatty Liver Disease · United States, Australia, Puerto Rico2CompletedNov 25, 2025212
NCT04972396Non-alcoholic Fatty Liver Disease · Australia1CompletedMay 15, 202240

How it is read

Names in the registry

  • “Pemvidutide”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.